



Public engagement highlights 2025

Annual overview of patients and healthcare professionals involvement in EMA's work



This year marked the start of the new 2025–2028 mandate for the PCWP and HCPWP, the election of new co-chairs, and the expansion of membership from 22 to 25 representatives. The EMA also released a draft reflection paper on patient experience data (PED) for public consultation. The European public assessment report template was updated to reflect PED and input from patients and healthcare professionals gathered during CHMP early dialogue. For more information, please see the [2024–25 Stakeholder Engagement Report](#).

Key events

EMA 30th Anniversary

In May 2025, EMA hosted its first Open Door Day. Participants visited the EMA building and learned about the work carried out by staff and experts from across Europe to ensure that medicines are safe and effective for human and animal health in the EU.

[EMA Open Door Day](#)

In June 2025, EMA held its 30th anniversary scientific conference to celebrate three decades of groundbreaking achievements and advancements in the field of medicine and regulatory science.

[EMA's 30th anniversary scientific conference - Medicines, regulation and the future](#)

Medicine shortages

In November 2025, EMA hosted a public webinar 'Putting patients first' for both patients and healthcare professionals to provide practical insights into EU medicine shortages activities. In parallel, the #ItTakesATeam campaign, co-created with PCWP and HCPWP, highlights EU efforts to tackle medicine shortages.

[Medicine shortages: EMA public webinar putting patients first](#)

[#ItTakesATeam campaign](#)

Stakeholder involvement in medicine-related activities

Patient contribution to EMA's work

Patient membership numbers	42
EMA Management Board	2
Scientific committees	15
Patients' and Consumers' Working party	25
Active patient/consumer experts	219
Patients/consumers eligible organisations	42

HCP contribution to EMA's work

HCP membership numbers	39
EMA Management Board	2
Scientific committees	12
HCP Working party	25
Active HCP experts	101
HCP eligible organisations	44

Working party meetings

April

Data Analysis and Real-World Interrogation Network (DARWIN EU), Update on Patient Experience Data, Risk Minimisation Measures, Product information, Update on European Medicines Agency Network (EMAN) Strategy, Shortages, Clinical trials

[Access meeting documents](#)

September

Election of new PCWP/HCPWP co-chairs, Update on Patient Experience Data, Scientific committees feedback, 30th anniversary events update, EMA interactions with academia and industry stakeholders

[Access meeting documents](#)

November

Update on revised pharmaceutical legislation, Clinical Trials updates, Real-World Evidence, Availability and supply of medicines, Gender equality and women's health, Product information updates, Communication and outreach activities, Members' voice


[Access meeting documents](#)

Patient and HCP engagement in medicine-specific activities

Patients in scientific advice procedures	53
Patients in scientific advisory groups	14
Patients in committee consultations	36
PCO responses to CHMP early dialogue	19
Review of documents by patients	108

HCP experts in scientific advisory groups	117
HCPOs in committee consultations	40
HCPOs responses to CHMP early dialogue	30
Review of documents by HCPs	37

Queries by stakeholder



Total number of queries: **1,353**

Overall satisfaction: **71%**

Common topics:

Adverse drug reactions, finasteride, availability, Covid-19 vaccines, Covid-19

More information

<https://www.ema.europa.eu/en/partners-networks/patients-consumers>

<https://www.ema.europa.eu/en/partners-networks/healthcare-professionals>

© European Medicines Agency, 2026

Reproduction is authorised provided the source is acknowledged. For any use or reproduction of images or other materials that are not under the copyright of the European Medicines Agency as specified subsequently, permission must be sought directly from the respective copyright holders. The indicated images or other materials are copyright protected and have been licensed by the European Medicines Agency via Adobe Stock, Dreamstime or iStockphoto, as shown respectively in the credit lines of each image or other material.



www.ema.europa.eu

An agency of the European Union

